ALXO

ALX Oncology Holdings Inc. (ALXO) | Rumor.io

ALX Oncology Holdings

ALXO

Attention (50-day avg)0%

Attention rank (50-day avg)#2,535

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.74

Market capitalization192.2M

Earnings per share-1.15

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-101.7M

Social

What share of all stock conversation is about ALXO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Feb 27

ALX Oncology Holdings Inc. reports strong 2025 results, with biomarkers validating CD47 as a predictor of evorpacept response.
Clinical programs for evorpacept and ALX2004 remain on track, with multiple data catalysts expected within 12-18 months.
The company anticipates its cash and investments to fund operating expenses through the first half of 2028, following a $140.4M financing in February 2026.

Generated by AI

Sentiment

Of the messages about ALXO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.42% -1.63
Bearish	—	—	—	16.58% +1.63

Bullish· Aug 27

$ALXO has a strong buying signal, with 84% of trades being buys, and a significant volume of 650,000 buys at the current high of day (HOD).
The stock has a "massive golden cross" from $0.94 to $1.25, indicating a strong uptrend and a potential price increase to $5.45 and eventually $9.00.
$ALXO has a low float of 37.38 million shares, which means that a small amount of buying can cause a significant price increase, potentially leading to a "massive squeeze" and a price explosion to $5.45 and $9.00.

Bearish· Jul 31

The stock has hit an all-time low, with a 52-week low of $3.98, despite positive news.
The company's news was not good enough for investors, who saw it as a "spin" on the results, leading to a decline in the stock.
The stock has a high short interest, with some reports suggesting 36% short interest, making it an easy target for short sellers.

Generated by AI

Topics

Of the messages about ALXO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	66.89%
Analysts	—	0%	0%	1.52%
Controversies	—	0%	0%	9.29%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	22.3%

Announcements· Jan 30

ALX Oncology Holdings Inc. (ALXO) announced a $150 million underwritten offering of common stock to fund clinical development programs, with shares priced at $1.57 per share.
The company reported preliminary findings from a clinical trial of its drug evorpacept, showing that CD47 expression may predict its effectiveness in HER2-positive metastatic breast cancer.
The financing is being led by new investors RA Capital Management and TCGX, with participation from additional new and existing investors, including several prominent healthcare-focused investment firms.

Controversies· Aug 26

ALX Oncology Holdings Inc. is being investigated for potential securities law violations related to its merger with LifeStance Health Group.
The investigation is focused on whether ALXO's management made false or misleading statements to investors about the merger.
The investigation is a securities class action lawsuit, which seeks to recover damages on behalf of ALXO shareholders.

Technical Analysis· Oct 3

The author notes a 56% pump in ALXO, a cancer stock, and mentions that many of these charts are bottomed, suggesting a potential turnaround.
A fake 5m flag pattern is identified in ALXO, but the author avoids taking the trade due to concerns about the high institutional ownership and thick float.
ALXO is seen as a potential trap due to its 77% institutional ownership, 21.68 million float, and $150 million ATM and $450 million shelf, with a clear level of $7.40 and massive orders on the tape.

Generated by AI

Community

Of the messages about ALXO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	86.36%	71.19%	68.77%
Newcomers	—	13.64%	28.81%	31.23%

Regulars· Oct 3

The positive interim phase 2 ASPEN-06 trial results for evorpacept in treating advanced HER2-positive gastric cancer showed a 55% vs 22% corrected overall response rate (CORR) by the anti-CD47 effect.
The control group in the ASPEN-06 trial performed significantly worse than the patients in the HER-RAM trial who received the same treatment, and more detailed information is needed to identify the reason for this.
The phase 3 portion of the ASPEN-06 trial is expected to start in late 2024, providing a potential catalyst for the stock.

Newcomers· Oct 4

$ALXO is considered a potential play for traders when the price is right, with a focus on finding a good level, range, and volume.
The stock is part of a group of biotech stocks that have been performing well due to positive news, trials, and data.
$ALXO has announced a share offering, but details have not been disclosed.

Generated by AI

News

ALX Oncology to Present at Upcoming Investor Conferences in September

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences. The details of the meetings are as follows: Wells Fargo 21st Annual Healthcare Conference Format: Fireside Chat and One-on-on

27d agoYahoo Finance

Alx oncology CEO Jason Lettmann disposes of $4,303 in shares

1mo agoInvesting.com

Also Discussed

Investors talking about ALXO also mention

#	Name	Attention
1	Shattuck Labs, Inc.STTK	0%new
2	I-Mab Sponsored ADRIMAB	0%0
3	Bicycle Therapeutics plc - ADRBCYC	0%0
4	Caribou Biosciences, Inc.CRBU	0%new
5	MRUS - Merus N.V.	——
6	PNT - POINT Biopharma Global Inc.	——
7	Western Asset Bond FundWABF	0%0
8	Janus Henderson Small/Mid Cap Growth Alpha ETFJSMD	0%0
9	MYOV - Myovant Sciences Ltd.	——
10	Zymeworks Inc.ZYME	0%0

ALX Oncology Holdings Inc.

Healthcare
Biotechnology

ALX Oncology Holdings Inc. is a clinical-stage biotechnology company focused on developing immuno-oncology therapies for cancer. Its lead program, evorpacept, is designed to block the CD47 pathway and is being studied in combination with other anti-cancer treatments across multiple solid tumor and blood cancer indications. The company’s pipeline also includes ALX2004, an epidermal growth factor receptor-targeted antibody-drug conjugate under development for EGFR-expressing tumors. ALX Oncology’s work centers on protein engineering, combination therapy research, and clinical studies aimed at addressing difficult-to-treat cancers. Based in South San Francisco, California, the company operates within the broader oncology drug development market and collaborates with clinical trial sites and research partners to advance its product candidates.

Website

Location

323 Allerton Avenue

South San Francisco, CA, 94080

United States

Social

What share of all stock conversation is about ALXO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

Feb 27

ALX Oncology Holdings Inc. reports strong 2025 results, with biomarkers validating CD47 as a predictor of evorpacept response.
Clinical programs for evorpacept and ALX2004 remain on track, with multiple data catalysts expected within 12-18 months.
The company anticipates its cash and investments to fund operating expenses through the first half of 2028, following a $140.4M financing in February 2026.

Generated by AI

Sentiment

Of the messages about ALXO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	83.42% -1.63
Bearish	—	—	—	16.58% +1.63

Bullish· Aug 27

$ALXO has a strong buying signal, with 84% of trades being buys, and a significant volume of 650,000 buys at the current high of day (HOD).
The stock has a "massive golden cross" from $0.94 to $1.25, indicating a strong uptrend and a potential price increase to $5.45 and eventually $9.00.
$ALXO has a low float of 37.38 million shares, which means that a small amount of buying can cause a significant price increase, potentially leading to a "massive squeeze" and a price explosion to $5.45 and $9.00.

Bearish· Jul 31

The stock has hit an all-time low, with a 52-week low of $3.98, despite positive news.
The company's news was not good enough for investors, who saw it as a "spin" on the results, leading to a decline in the stock.
The stock has a high short interest, with some reports suggesting 36% short interest, making it an easy target for short sellers.

Generated by AI

Topics

Of the messages about ALXO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	66.89%
Analysts	—	0%	0%	1.52%
Controversies	—	0%	0%	9.29%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	22.3%

Announcements· Jan 30

ALX Oncology Holdings Inc. (ALXO) announced a $150 million underwritten offering of common stock to fund clinical development programs, with shares priced at $1.57 per share.
The company reported preliminary findings from a clinical trial of its drug evorpacept, showing that CD47 expression may predict its effectiveness in HER2-positive metastatic breast cancer.
The financing is being led by new investors RA Capital Management and TCGX, with participation from additional new and existing investors, including several prominent healthcare-focused investment firms.

Controversies· Aug 26

ALX Oncology Holdings Inc. is being investigated for potential securities law violations related to its merger with LifeStance Health Group.
The investigation is focused on whether ALXO's management made false or misleading statements to investors about the merger.
The investigation is a securities class action lawsuit, which seeks to recover damages on behalf of ALXO shareholders.

Technical Analysis· Oct 3

The author notes a 56% pump in ALXO, a cancer stock, and mentions that many of these charts are bottomed, suggesting a potential turnaround.
A fake 5m flag pattern is identified in ALXO, but the author avoids taking the trade due to concerns about the high institutional ownership and thick float.
ALXO is seen as a potential trap due to its 77% institutional ownership, 21.68 million float, and $150 million ATM and $450 million shelf, with a clear level of $7.40 and massive orders on the tape.

Generated by AI

Community

Of the messages about ALXO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	86.36%	71.19%	68.77%
Newcomers	—	13.64%	28.81%	31.23%

Regulars· Oct 3

The positive interim phase 2 ASPEN-06 trial results for evorpacept in treating advanced HER2-positive gastric cancer showed a 55% vs 22% corrected overall response rate (CORR) by the anti-CD47 effect.
The control group in the ASPEN-06 trial performed significantly worse than the patients in the HER-RAM trial who received the same treatment, and more detailed information is needed to identify the reason for this.
The phase 3 portion of the ASPEN-06 trial is expected to start in late 2024, providing a potential catalyst for the stock.

Newcomers· Oct 4

$ALXO is considered a potential play for traders when the price is right, with a focus on finding a good level, range, and volume.
The stock is part of a group of biotech stocks that have been performing well due to positive news, trials, and data.
$ALXO has announced a share offering, but details have not been disclosed.

Generated by AI

ALX Oncology Holdings

Social

Feb 27

Bullish· Aug 27

Bearish· Jul 31

Announcements· Jan 30

Controversies· Aug 26

Technical Analysis· Oct 3

Regulars· Oct 3

Newcomers· Oct 4

ALX Oncology reports trial data for gastric cancer drug

ALX Oncology at H.C. Wainwright conference: two drug bets near key tests

ALX Oncology at Cantor healthcare conference: biomarker push takes center stage

ALX Oncology at Wells Fargo conference: two drugs near key tests

ALX Oncology to Present at Upcoming Investor Conferences in September

Alx oncology CEO Jason Lettmann disposes of $4,303 in shares

Also Discussed

ALX Oncology Holdings Inc.

Company Information

Location

Social

Feb 27

Bullish· Aug 27

Bearish· Jul 31

Announcements· Jan 30

Controversies· Aug 26

Technical Analysis· Oct 3

Regulars· Oct 3

Newcomers· Oct 4

ALX Oncology reports trial data for gastric cancer drug

ALX Oncology at H.C. Wainwright conference: two drug bets near key tests

ALX Oncology at Cantor healthcare conference: biomarker push takes center stage

ALX Oncology at Wells Fargo conference: two drugs near key tests

ALX Oncology to Present at Upcoming Investor Conferences in September

Alx oncology CEO Jason Lettmann disposes of $4,303 in shares

Also Discussed